The results you suggest are significant at p
Post# of 148282
The suggested .045 is not the required result at interim analysis.
As I understand the penalty, is relates to the required significance at 390 enrollees, assuming it is not ended early. It translates to 1 to 2 fewer deaths in the 260 person leronlimab arm.
My view: dissemination of very good results, even if they don't cause a halt for efficacy, will accelerate remaining enrollment.